The only way to improve cancer detection, prevention, and treatment is through research. People participating in research contribute to medical knowledge and have opportunity to receive cutting-edge care.
Our Featured Research Page lists cancer prevention, treatment and quality of life studies enrolling people with or at high risk for hereditary cancers. You can do a quick search to filter our featured studies by cancer type, study type or key word, or a more in-depth search through clinicaltrials.gov.
Opening the Conversation
Clinicaltrials.gov identifier:
NCT04806724
Quality of Life
Online communication program for breast and gynecologic cancer survivors and their partners
A Study to Compare Two Surgical Procedures in Women with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer (SOROCk)
Clinicaltrials.gov identifier:
NCT04251052
Prevention
PARP Inhibitor (Niraparib) in Patients with Inherited or Tumor PALB2 Mutations in Advanced Solid Tumors (PAVO)
Clinicaltrials.gov identifier:
NCT05169437
Treatment
Any advanced or metastatic solid tumor except ovarian or prostate
Men at High Genetic Risk for Prostate Cancer
Clinicaltrials.gov identifier:
NCT03805919
Prevention
Prostate screening with MRI for men with Lynch syndrome or a BRCA1/2, ATM, BRIP1, CHEK2, PALB2, RAD51C/D, TP53, HOXB13, FANCA or NBN mutation
Combined Pembrolizumab & Quavonlimab (MK-1308A) Versus Other Treatments in People With MSI-High or dMMR Stage IV Colorectal Cancer
Clinicaltrials.gov identifier:
NCT04895722
Treatment
Stage 4 colorectal cancer
Pancreatic Cancer Early Detection for People at High Risk
Clinicaltrials.gov identifier:
NCT04970056
Prevention
Registry and biobank for high risk people undergoing pancreatic cancer screening
Survey for People Diagnosed with Breast Cancer to Provide Feedback on a New Type of Clinical Trial
Surveys, Registries, Interviews
Survey for people diagnosed with stage 0 - stage 3 breast cancer
Pancreatic Cancer Screening Study(CAPS5)
Clinicaltrials.gov identifier:
NCT02000089
Prevention
Screening study for people at high risk for pancreatic cancer
Combination ATR inhibitor and PARP Inhibitor in Recurrent Ovarian Cancer (CAPRI)
Clinicaltrials.gov identifier:
NCT03462342
Treatment
Recurrent ovarian cancer
Effect of Acupuncture on Memory and Thinking Difficulties after Breast Cancer
Clinicaltrials.gov identifier:
NCT04837820
Quality of Life
Acupuncture study for people with memory issues who completed treatment for stage 0-3 breast cancer
Restoring Sensation after DIEP Flap Reconstruction
Clinicaltrials.gov identifier:
NCT04533373
Prevention
Study for people undergoing DIEP flap reconstruction
Denosumab for Preventing Breast Cancer in Women with a BRCA1 Inherited Mutation (BRCA-P)
Clinicaltrials.gov identifier:
NCT04711109
Prevention
Prevention study enrolling women ages 25-55 with a BRCA1 mutation
Effects of Occupational Therapy Telehealth Intervention on Cancer-Related Cognitive Impairment in Breast Cancer Survivors
Clinicaltrials.gov identifier:
NCT05505045
Quality of Life
Telehealth study for breast cancer survivors with memory issues
Differences in Family Communication about Positive Genetic Test Results Between Asian Americans
Surveys, Registries, Interviews
Interview for Asian Americans with a mutation in BRCA1, BRCA2, ATM, CHEK2, PALB2 or other gene linked to breast or ovarian cancer risk
Physical Activity Promotion for Breast and Endometrial Cancer Survivors
Clinicaltrials.gov identifier:
NCT04262180
Quality of Life
Exercise study for breast or endometrial cancer survivors
Survey about Endometrial Cancer Risk and Risk-Reducing Surgery for Women with a BRCA1/2 Mutation or Mutation in the Family
Surveys, Registries, Interviews
Women with a BRCA mutation or from a family with a BRCA mutation
Tools To Be Fit: Tools to Improve Nutrition and Physical Activity for Colorectal Cancer Survivors
Clinicaltrials.gov identifier:
NCT05056077
Quality of Life
Nonmetastatic colon or rectal cancer
Factors Influencing Disparities in Quality of Life among People of Color Affected by Cancer
Surveys, Registries, Interviews
Survey for people of color who have completed treatment for cancer
Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS)
Clinicaltrials.gov identifier:
NCT05129605
Prevention
People at high risk for prostate cancer due to an inherited mutation
NUV-868 Alone and in Combination With PARP Inhibitors in Patients With Advanced Solid Tumors
Clinicaltrials.gov identifier:
NCT05252390
Treatment
Treatment study for people with advanced solid tumors, including triple-negative breast, ovarian, pancreatic and prostate cancer
Assessing Decisions about Uterine and Ovarian Cancer Prevention by People with Lynch Syndrome
Surveys, Registries, Interviews
Online survey for people with Lynch syndrome
Opening the Conversation Study
Clinicaltrials.gov identifier:
NCT04806724
Quality of Life
Videoconference sessions that address cancer related concerns for couples
EnergyPoints: A Mobile App Guiding Use of Acupressure for Cancer-related Fatigue and Sleep Disturbances
Quality of Life
Anyone diagnosed with cancer experiencing fatigue
Studying the Medication Olaparib Given with Radium-223 for Advanced Prostate Cancer with Bone Metastasis
Clinicaltrials.gov identifier:
NCT03317392
Treatment
People with castration-resistant prostate cancer with bone spread
Adding PARP Inhibitor to Enzalutamide to Treat Men with Metastatic Prostate Cancer that is Resistant to Anti-androgen Therapy
Clinicaltrials.gov identifier:
NCT04455750
Treatment
Treatment study for men with metastatic prostate cancer
Physical Activity at Home for Relief from Neuropathy Caused by Taxanes in People with Breast Cancer
Clinicaltrials.gov identifier:
NCT04621721
Quality of Life
Quality of life study for breast cancer patients experiencing neuropathy from chemotherapy
Studying Types of Therapy for Coping With Fear of Recurrence Among Breast Cancer Survivors
Clinicaltrials.gov identifier:
NCT05364450
Quality of Life
People with stage 1-3 breast cancer who completed treatment within 5 years of enrollment
Treating Metastatic Prostate Cancer with Chemotherapy or PARP Inhibitor in People with Mutations (COBRA)
Clinicaltrials.gov identifier:
NCT04038502
Treatment
Treatment study for mCRPC with an inherited or tumor mutation in BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D or RAD54L
Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women
Clinicaltrials.gov identifier:
NCT05287451
Prevention
Prevention study for women at high risk for ovarian cancer
TALAPRO-3: A Clinical Trial in Men with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) and DNA Damage Repair (DDR) Gene Alteration
Clinicaltrials.gov identifier:
NCT04821622
Treatment
Metastatic castration-sensitive prostate cancer
Abiraterone/Prednisone and Olaparib Alone or In Combination for Treatment of Metastatic Castration-Resistant Prostate Cancer With Mutations Related to DNA Repair
Clinicaltrials.gov identifier:
NCT03012321
Treatment
Men with mCRPC with an inherited mutation or a tumor mutation in a DNA damage repair gene
Treatment for Metastatic Castration-Sensitive Prostate Cancer and Inherited or Tumor Mutations in DNA Damage Repair Genes (Amplitude)
Clinicaltrials.gov identifier:
NCT04497844
Treatment
Treatment for metastatic castration-sensitive prostate cancer and a tumor or inherited mutation in BRCA1, BRCA2, ATM, BRIP1, CHEK2, PALB2 or related gene
Exploring the Fertility Preservation Needs of Individuals with Positive Genetic Test Results
Surveys, Registries, Interviews
Survey and video interview for people who tested positive for an inherited mutation
Factors Influencing Reproductive Decision-Making in Individuals with a BRCA1 or BRCA2 Gene Mutation
Surveys, Registries, Interviews
Survey for people with a BRCA1 or BRCA2 mutation
Bazedoxifene Plus Conjugated Estrogens for Hot-Flashes in Women at High Risk for Breast Cancer
Clinicaltrials.gov identifier:
NCT04821141
Quality of Life
Women at high risk for breast cancer due to ATM, CDH1, CHEK2, NBN, NF1, PALB2, PTEN, STK11, P53 or PTEN mutation who have hot-flashes
Interview Study about Barriers to Genetic Testing of Family Members in Latin America
Surveys, Registries, Interviews
People with a hereditary cancer gene mutation and relatives living in Latin America
Research Opportunity for Previvors and their Romantic Partners
Surveys, Registries, Interviews
Interview for people with inherited mutations who had risk-reducing mastectomy and their partners
Young, Empowered & Strong: Web-Based Symptom Monitoring and Self-Management for Young Adult Breast Cancer Survivors
Clinicaltrials.gov identifier:
NCT04906200
Quality of Life
Women diagnosed with breast cancer between the ages of 15-39
BRCA 1 and 2: Interviews on Genetic Testing and Individual Experiences
Surveys, Registries, Interviews
People with or without cancer who have had or are considering BRCA testing
Combination Drugs for Treating Metastatic Castration-resistant Prostate Cancer with Tumor Mutation that Affect DNA Repair
Clinicaltrials.gov identifier:
NCT03012321
Treatment
Treatment study for men with metastatic castration-resistant prostate cancer
Zoom Interviews to Explore Ideas about Long-Term Follow-Up Cancer Genetic Counseling
Surveys, Registries, Interviews
Interviews with adults that have recently met with a cancer genetic counselor in the U.S., regardless of genetic testing outcome
SHARON: A Clinical Trial for Metastatic Cancer With an Inherited BRCA or PALB2 Mutation Using Chemotherapy and Patients’ Own Stem Cells
Clinicaltrials.gov identifier:
NCT04150042
Treatment
Advanced pancreatic cancer or stage 4 breast cancer in people with a BRCA1 or BRCA2 mutation
Metastatic Pancreatic Cancer in US
Surveys, Registries, Interviews
People with metastatic pancreatic cancer and their caregivers
Interviews for people with a genetic test result that was later reclassified
Surveys, Registries, Interviews
People with a genetic test result that was later reclassified
Chemotherapy, Immunotherapy and PARP Inhibitor for the Treatment of Metastatic Aggressive Variant Prostate Cancer (AVPC)
Clinicaltrials.gov identifier:
NCT04592237
Treatment
Treatment in people with aggressive metastatic prostate cancer
Studying Crowdfunding for Cancer
Surveys, Registries, Interviews
Cancer survivors who have used crowdfunding to help cover cancer-related costs
Treating Early-Stage Breast Cancer with a PARP Inhibitor (Niraparib) and Immunotherapy (Dostarlimab) in People with a BRCA or PALB2 Mutation
Clinicaltrials.gov identifier:
NCT04584255
Treatment
Treatment before surgery for people with early-stage breast cancer & a BRCA1, BRCA2 or PALB2 mutation
Androgen Suppression With Abiraterone, Leuprolide, PARP Inhibitor and Stereotactic Radiotherapy in Prostate Cancer (ASCLEPIuS)
Clinicaltrials.gov identifier:
NCT04194554
Treatment
Newly diagnosed prostate cancer grade group 3-5
Investigational PARP Inhibitor AZD5305 Alone or Combined With Other Anti-cancer Agents in People With Advanced Solid Tumors (PETRA)
Clinicaltrials.gov identifier:
NCT04644068
Treatment
Advanced ovarian, breast, prostate or pancreatic cancer
Interview about Hispanic/Latino Community Experiences Accessing Genetic Testing for Hereditary Cancer Risk
Surveys, Registries, Interviews
Hispanic/Latino people with a personal diagnosis of cancer or a family history of cancer
Targeted Therapy RP-3500 Alone or in Combination with Talazoparib or Gemcitabine in Advanced Solid Tumors with DNA Damage Repair Mutations (TRESR Study)
Clinicaltrials.gov identifier:
NCT04497116
Treatment
Advanced solid tumors
Screening for Cancer DNA in the Blood after Treatment for Early-Stage TNBC and/or a BRCA Mutation; Followed by Study Comparing Niraparib with Placebo for People with Cancer DNA found in their Blood (ZEST)
Clinicaltrials.gov identifier:
NCT04915755
Treatment
Early-stage TNBC or early-stage breast cancer with a BRCA mutation
ATR Inhibitor Plus Niraparib Study in Advanced Solid Tumors and Ovarian Cancer
Clinicaltrials.gov identifier:
NCT04267939
Treatment
Advanced ovarian cancer or other solid tumors
Inherited Cancer Registry (ICARE): Contribute to Research While Staying Informed
Clinicaltrials.gov identifier:
NCT03231891
Surveys, Registries, Interviews
People with an inherited mutation or cancer in the family
Adding Pembrolizumab to Olaparib to Treat Pancreatic Cancer in People with an Inherited BRCA Mutation
Clinicaltrials.gov identifier:
NCT04548752
Treatment
Metastatic pancreatic cancer and a BRCA1 or BRCA2 mutation
A Study of the Investigational Targeted Therapy ART4215 to Treat Advanced or Metastatic Solid Tumors
Clinicaltrials.gov identifier:
NCT04991480
Treatment
Advanced solid tumors
Survey: How Willing are You to Participate in Different Types of Clinical Trials for the Prevention of Breast Cancer?
Surveys, Registries, Interviews
Retifanlimab Alone or with Other Agents for Advanced Endometrial Cancer that Progressed with Platinum
Clinicaltrials.gov identifier:
NCT04463771
Treatment
Advanced endometrial cancer
Testing a Vaccine for Cancer Prevention in People with a BRCA1 or BRCA2 Mutation
Clinicaltrials.gov identifier:
NCT04367675
Prevention
People with a BRCA1 or BRCA2 mutation
Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects
Clinicaltrials.gov identifier:
NCT04030559
Treatment
High-risk localized prostate cancer
Treatment with ATR Inhibitor for Advanced or Metastatic Solid Tumors
Clinicaltrials.gov identifier:
NCT04657068
Treatment
Advanced solid tumors
Treating Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer with Chemotherapy and Rucaparib
Clinicaltrials.gov identifier:
NCT03337087
Treatment
Metastatic colorectal, pancreatic, gastroesophageal or biliary tract cancer
CYH33 in Combination With Olaparib in Patients With Advanced Solid Tumors and DNA Damage Repair Mutations
Clinicaltrials.gov identifier:
NCT04586335
Treatment
Advanced solid tumors
Nivolumab and Relatlimab in Advanced MSI-H Cancers Resistant to Prior PD-L1 Inhibitor
Clinicaltrials.gov identifier:
NCT03607890
Treatment
Solid tumors that are MSI-High and resistant to prior immunotherapy
Atorvastatin ± Aspirin for Colorectal Cancer Prevention for People with Lynch Syndrome
Clinicaltrials.gov identifier:
NCT04379999
Prevention
Olaparib, Palbociclib and Fulvestrant for BRCA-Associated, ER/PR-Positive, Her2-Negative Metastatic Breast Cancer
Clinicaltrials.gov identifier:
NCT03685331
Treatment
Blood Markers of Early Pancreas Cancer
Clinicaltrials.gov identifier:
NCT03568630
Prevention
Screening for people with family history of pancreas cancer or an inherited mutation linked to pancreatic cancer risk.
Treating Metastatic Pancreatic Cancer with an Inherited or Tumor BRCA1/2 or PALB2 Mutation with Niraparib and Dostarlimab
Clinicaltrials.gov identifier:
NCT04493060
Treatment
AMPLIFY: a new online weight loss study specifically for cancer survivors!
Clinicaltrials.gov identifier:
NCT04000880
Quality of Life
Developing a Test for the Detection of Ovarian Cancer
Clinicaltrials.gov identifier:
NCT04794322
Prevention
PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness
Clinicaltrials.gov identifier:
NCT04995198
Surveys, Registries, Interviews
Chemotherapy, Bevacizumab, and/or Atezolizumab for dMMR / MSI-H Metastatic Colorectal Cancer (COMMIT Study)
Clinicaltrials.gov identifier:
NCT02997228
Treatment
Screening for Pancreatic Cancer in Patients with an Inherited BRCA1, BRCA2, PALB2 or ATM Mutation
Clinicaltrials.gov identifier:
NCT02478892
Prevention
Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation
Clinicaltrials.gov identifier:
NCT04858334
Treatment
Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations
Clinicaltrials.gov identifier:
NCT04042831
Treatment
Validating a Blood Test for Early Ovarian Cancer Detection in High-risk Women and Families
Prevention
Screening study for women with a BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, PMS2, MLH1, MSH2, MSH6, or EPCAM mutation
Nivolumab, Nivolumab Plus Ipilimumab, or Chemotherapy for Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (CheckMate 8HW)
Clinicaltrials.gov identifier:
NCT04008030
Treatment
People with metastatic colorectal cancer that is MSI-High
Pembrolizumab and Olaparib for Metastatic Pancreatic Cancer with Homologous Recombination Deficiency or Exceptional Response to Platinum Chemotherapy
Clinicaltrials.gov identifier:
NCT04666740
Treatment
PARP Inhibitor for Metastatic Prostate Cancer With DNA Repair Defects
Clinicaltrials.gov identifier:
NCT03012321
Treatment
Mobile Mindfulness Meditation Intervention to Improve Neuropathy in Cancer Survivors
Clinicaltrials.gov identifier:
NCT03581357
Quality of Life
Mobile Mindfulness Meditation Intervention for Cancer Survivors
Clinicaltrials.gov identifier:
NCT03581357
Quality of Life
A Survey on Options for Managing Cancer Risk Among Women with a BRCA1 or BRCA2 Mutation
Surveys, Registries, Interviews
Olaparib Expanded - Treating Metastatic Breast Cancer in People without gBRCA Mutations
Clinicaltrials.gov identifier:
NCT03344965
Treatment
The Risk Factor Analysis of Hereditary Breast and Ovarian Cancer In Women with BRCA1, BRCA2 or PALB2 Mutations
Surveys, Registries, Interviews
Diagnosis of Breast Cancer in Young Women - Share Your Story
Surveys, Registries, Interviews
Talazoparib for people with metastatic breast cancer who have acquired (somatic) BRCA mutations
Clinicaltrials.gov identifier:
NCT03990896
Treatment
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Clinicaltrials.gov identifier:
NCT02912559
Treatment
Genetic Testing for Men with Metastatic Prostate Cancer (GENTleMEN Study)
Clinicaltrials.gov identifier:
NCT03503097
Treatment
Pancreatic Cancer Screening Study for High Risk People
Clinicaltrials.gov identifier:
NCT03250078
Prevention
Denosumab and Mammographic Density in Premenopausal Women With Dense Breasts (TRIDENT)
Clinicaltrials.gov identifier:
NCT04067726
Prevention
Study for People with Unexpected Genetic Results
Clinicaltrials.gov identifier:
NCT02595957
Prevention
.jpg)
Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job
Clinicaltrials.gov identifier:
NCT03572374
Quality of Life
INTERVAL: INTense Exercise foR surVivAL in Men With Metastatic Prostate Cancer
Clinicaltrials.gov identifier:
NCT02730338
Quality of Life
RADCOMP: A Study at the Heart of Breast Cancer Treatment
Clinicaltrials.gov identifier:
NCT02603341
Treatment
Identification and Analysis of Families With Genetic Susceptibility To Cancer Registry
Surveys, Registries, Interviews
.jpeg)
Search Research Studies
Sponsored By:
